New PET scan tested for finding colon cancer spread
Tests a new PET/CT scan tracer in adults with colon cancer.
Plain-language title generated from the registry record
Registry title: Colon Cancer Diagnosis With FAPI-PET Imaging
Key facts
- Where
- Turku, FinlandSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07272772, who can take part
Where in Finland
- Turku PET Centre, Turku University HospitalTurku, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- NCT07272772
- Record updated
- 9 December 2025
- Original description
Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targeting a protein that is overexpressed by cancer-associated fibroblasts presents a potential new PET imaging tool.Read full original descriptionShow less
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients With Colon Cancer
Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targeting a protein that is overexpressed by cancer-associated fibroblasts presents a potential new PET imaging tool.
The objective of this prospective study is to evaluate diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with colon cancer in primary staging and when suspected recurrence. 100 patients with colon cancer are enrolled and PET/CT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.
Inclusion: Patients with primary colon cancer with suspicion of mesenteric lymph node metastases in computed tomography before primary cancer operation; Patients with primary colon cancer with potentially curable metastases; Patients with suspected metastasis or local recurrence in computed tomography and/or elevated carcinoembryonic antigen (CEA) in cancer surveillance; WHO performance score 0-2; Patient signs informed consent form after receiving written information.
Exclusion: Medical conditions prohibiting whole body PET-CT; Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included; Patient is not able to understand purpose of study.